Articles tagged with Melanoma
Researchers analyzed data from large-scale studies of erectile dysfunction medication users and found an overall 11% increase in melanoma risk. However, they attribute the increased risk to detection bias rather than a direct cause-and-effect link between medications and melanoma.
Researchers have discovered that FES, a protein previously linked to cancer development, actually acts as a tumor suppressor in melanoma. The study found that restoring FES expression through epigenetic drugs may provide a novel therapeutic strategy against melanoma.
The Melanoma Research Alliance awarded Dr. Neville Sanjana a grant to use CRISPR technology to identify genetic mutations causing immunotherapy resistance in melanoma. The goal is to create a list of actionable mutations for patients enrolled in melanoma immunotherapy trials.
Researchers analyzed data on 2,025 women diagnosed with stage I to IV melanoma and found no significant differences in prognosis between pregnant and non-pregnant patients. The study upends long-held beliefs about pregnancy and melanoma, showing that screening and treatment should be similar for both groups.
Researchers found significant evidence that inhibiting protein TERT may aid in diagnosis and treatment of acral lentiginous melanoma (ALM). In laboratory experiments, over 75% of ALM cancer cells were affected by a drug that inhibits TERT.
The article reviews current screening practice for melanoma in the US, highlighting risk groups and proposing full screening recommendations. The authors critically assess the USPSTF's 2016 Draft Recommendation Statement and propose evidence-based guidelines for screenings.
Researchers have identified mutations in the SF3B1 gene present in 37% of mucosal melanoma samples, which could lead to novel therapies. The study highlights the potential of targeting this gene in patients with advanced mucosal melanoma.
A gene variant that produces red hair and fair skin in humans and mice has been found to contribute to the association between melanoma and Parkinson's disease. The study shows that mice carrying this variant have reduced dopamine production and increased sensitivity to toxins, making them more susceptible to neurodegeneration.
A study found that while melanoma survivors limit sun exposure, some still seek out tans and get sunburns. Survivors reported suboptimal behaviors, with 20% getting sunburned in the previous year.
Researchers have successfully imaged the two dominant melanin molecules using a refined Raman-based technique, CARS microscopy. This breakthrough could lead to new understandings and early detection of melanoma, particularly in cases where pheomelanin is present.
Researchers found that loss of tumor-suppressing genes, not mutations, leads to resistance to immune checkpoint blockade drugs in melanoma. Anti-CTLA4 treatment can prime T cells for anti-PD1 therapy, improving patient response.
A study published in The Journal of the American Osteopathic Association found that young adults with high melanin content skin are at increased risk of sunburn. Researchers suggest that targeted sunburn prevention programs, including apps that gamify protection, could help reduce this risk.
Scientists at The Wistar Institute have identified an anti-aging gene that inhibits a protein involved in metastatic progression and resistance to targeted therapies. Activating this gene with an anti-diabetic drug may provide a promising adjuvant therapy for older melanoma patients.
A study found that patients with metastatic melanoma who responded to PD1 checkpoint inhibitor therapy had a greater diversity of gut bacteria and larger volumes of specific bacteria than non-responders. The researchers also discovered increased immune infiltrates in responders' tumors, correlated to the abundance of a specific bacterium.
Researchers analyzed data from over 580 patients with stage II melanoma and found that 40% of recurrences were spotted by patients due to suspicious skin changes or other symptoms. Patients are encouraged to regularly examine their skin and report any new or unusual symptoms to their physicians.
A new immunotherapy, pembrolizumab, has shown significant activity against mucosal melanoma tumors and prolonged survival in patients with bladder cancer. The treatment demonstrated a response rate of 16% and improved overall survival rates compared to chemotherapy.
Researchers predict that melanoma death rates will decrease by 2050 due to the aging of populations, but the number of deaths may increase. Effective treatments could lead to a further decline in mortality rates.
According to the study, 11 of the 49 states with reported melanoma incidence rates saw a decrease, while 38 states experienced an increase. The researchers suggest that better treatment may be prolonging the life of patients with melanoma.
A new study reports an estimated 76,380 Americans will be diagnosed with melanoma in 2016, with current lifetime risk being 1 in 54 for invasive melanoma. The overall burden of disease is increasing, with rising rates and higher mortality rates, exceeding the previous estimate of 10,130 deaths
Research finds that pembrolizumab is a cost-effective first-line treatment for advanced melanoma, offering improved survival and progression-free rates compared to ipilimumab and cytotoxic chemotherapy. The study suggests that healthcare authorities should consider including pembrolizumab as a reimbursable item in the public setting.
Research at McGill University has identified a link between decreased X chromosome gene PPP2R3B expression and tumor progression in melanoma. The findings suggest that genetic specificity of the X chromosome plays a role in gender differences observed in melanoma prognosis.
A Northwestern Medicine study shows that trained partners can catch far more mole irregularities than control group participants, growing their confidence and trust along the way. Common areas prone to developing fatal melanoma include hard-to-see spots on the body.
Recent developments in dendritic cell vaccines and oncolytic immunotherapy have led to improved outcomes in melanoma patients. Various vaccine candidates are being developed and tested in clinical trials, offering new avenues for treating this malignancy.
Researchers at LSU Health New Orleans report a complete response in a patient with long history of melanoma after treatment with a combination of an interferon and melanoma vaccine. The FDA has approved a first-of-its-kind therapy, talimogene laherparepvec, which shows a 10.8% complete response rate.
A study published in Cancer Epidemiology, Biomarkers & Prevention found that alcohol intake is associated with a higher risk of invasive melanoma, especially among individuals who consume more than 20 grams of alcohol per day. White wine was the most clearly associated with increased risk.
A Penn study found that decreased levels of the gene p15 can distinguish nevi from melanomas. The protein p15 inhibits nevus cell proliferation and can be used as a biomarker to identify borderline cases.
A new study suggests that identifying patients with higher risk factors, such as many moles or family history of melanoma, can improve the identification and treatment of those at higher risk. The study found that these patients were more likely to have melanoma on specific areas of their skin.
A study by the University of Texas MD Anderson Cancer Center found that 81% of indoor tanning facilities complied with the Texas ban on indoor tanning for those under 18. The study also showed that daily use practices exceeded FDA guidelines, and most facilities indicated that burns are possible with indoor tanning.
A study published in JAMA Dermatology found that patients with a family history of melanoma, multiple primary melanomas, or many moles are at higher risk for developing melanoma. The researchers recommend tailoring surveillance programs to individual risk factors to improve early detection and treatment.
Researchers found a combination of immunotherapy options improves overall survival and lowers the risk of life-threatening events in late-stage melanoma patients. PD-1 inhibitors were associated with the lowest risk of life-threatening events, making them a promising first-line therapy option.
A phase III trial found ipilimumab as adjuvant therapy significantly improved overall survival in patients with high-risk stage III melanoma, reducing relative risk of death by 28% at 5.3 years median follow-up.
A survey by Dr Lidija Kandolf-Sekulovic found that over 5000 European melanoma patients are denied access to innovative treatments each year. In Eastern Europe, only 42% of countries have registered the treatment, and only 18% have full reimbursement coverage.
A survey found that over 5,000 metastatic melanoma patients in Europe are denied access to innovative treatments annually. The inequality affects Eastern and South-Eastern European countries more severely, where only 10% of patients have access to the latest treatment recommended by current guidelines.
Researchers have identified the ATG5 protein as a key regulator of metastatic capacity in melanomas. The study found that patients with partial loss of the ATG5 gene have a worse prognosis, developing metastasis and resistance to drugs.
Researchers discovered that melanoma sends tiny vesicles containing microRNA before spreading, inducing morphological changes in the dermis. They found promising chemical substances to block this process, offering hope for a cure for the deadly disease.
New research links specific inherited genetic differences to an increased risk for eye melanoma, a rare form of melanoma arising from pigment cells that determine eye color. Genetic mutations associated with skin melanoma were also found to be linked to uveal melanoma risk.
A retrospective clinical study found that patients with melanoma who received both ipilimumab and local peripheral treatments had significantly prolonged overall survival compared to those who received only ipilimumab. The median overall survival for these patients was 93 weeks, compared to 42 weeks for those receiving only ipilimumab.
A task force has been criticized for not recommending melanoma screening due to lack of evidence, but dermatologists believe early detection reduces risk of death from melanoma through visual inspections. The issue highlights the need for refined standards on skin cancer screenings with potential life-saving benefits.
A new study of over 1,000 primary care melanoma screenings found no significant increase in surgical treatments or specialist referrals. The practice did result in a 79% increase in per-patient melanoma diagnoses among the most trained group, but this was not associated with an increase in dermatologist visits or surgeries.
Patients with melanoma and their partners can help detect early signs of a second primary melanoma with skin self-examination. A clinical trial found that trained partners identified 43 new melanomas, compared to none in the control group.
Regular skin checks during PCP visits improve melanoma detection and treatment outcomes. Thinner melanomas detected through screening have a better prognosis than thicker ones.
Researchers successfully treated a patient with metastatic melanoma using a combined approach of immunotherapy, including IL-21-primed polyclonal CTL plus CTLA4 blockade. The treatment led to the complete disappearance of tumors and sustained disease-free status for five years.
A study by Sanford Burnham Prebys Medical Discovery Institute identified a super-oncogenic protein, activating transcription factor 2 (ATF2), that drives the formation of melanoma in mice with BRAF mutations. Inactive ATF2 was found to cause tumors to develop slower than expected, making it a potential indicator of tumor aggressiveness.
Researchers found that a tumor suppressor gene helps repair UV damage in cells, reducing the risk of skin cancers like melanoma. The study suggests this gene may serve as a biomarker for skin cancer prevention and offers hope for new drug targets.
A multicenter prospective study found that untreated severe obstructive sleep apnea is associated with increased aggressiveness of malignant cutaneous melanoma. The study involved 412 patients and showed a relationship between sleep apnea and poor prognosis markers for melanoma.
Research suggests that melanomas from the South Island of New Zealand are more likely to carry gene mutations affecting treatment outcomes. The study found significantly higher rates of NRAS mutations in South Island patients compared to those from the North Island, with implications for targeted drug therapies and patient outcomes.
Dr. Murtaza and Dr. Antoni Ribas are awarded $200,000 to investigate whether microbiome analysis can predict patient response to immunotherapy in melanoma patients. Their study aims to analyze the relationship between microbial composition and immunotherapy outcomes.
The white paper outlines key takeaways, including the importance of proper sunscreen use to reduce melanoma risk by up to 50%, developing more precise diagnosis methods, and overcoming immunotherapy resistance. The research aims to advance treatment and potentially cure melanoma by understanding its unique characteristics.
A hospital-based study found carriers of MC1R variants were at higher risk of melanoma, regardless of sun exposure. The study suggests a potential molecular mechanism underlying melanoma development.
Researchers developed a microneedle patch that delivers anti-PD-1 antibodies directly to the site of melanoma skin cancer, improving treatment effectiveness. The patch creates a sustained release of antibodies into the tumor microenvironment, achieving better retention and efficacy compared to traditional treatments.
Researchers at VIB, KU Leuven and UGent have discovered a non-coding RNA gene called SAMMSON that is specifically expressed in human malignant melanoma. The growth of aggressive skin cancer is highly dependent on this gene, paving the way for improved diagnostic tools and treatment options.
A new blood test can detect early warning signs of skin cancer relapse in advanced melanoma patients by tracking levels of circulating tumour DNA. The test identifies new mutations in genes like NRAS and PI3K, which may cause the relapse.
Most melanoma patients had zero to 20 total moles and no atypical moles. In younger patients under 60, having few total moles reduced the risk of thick melanomas, while having more atypical moles increased tumor thickness.
A new biomarker, PRAME mRNA, has been identified as a key indicator of high-risk uveal melanoma patients who are more likely to develop metastasis. This discovery may lead to the development of precision medicines for melanoma patients.
Current diagnostic techniques make aggressive treatment unnecessary for many patients with metastasized skin cancer. The Sunbelt Melanoma Trial found that interferon therapy offered no benefits for stage III melanoma patients with minimal lymph node involvement.
A study published in JAMA Dermatology found that women younger than 40 who were diagnosed with melanoma had initiated indoor tanning at an earlier age and reported more frequent tanning. The study suggests that indoor tanning is a significant risk factor for developing melanoma, especially among young women.
Researchers discovered an inherited genetic marker associated with less favorable melanoma survival, while another variant showed a stronger correlation with better survival. These findings could lead to the development of personalized treatment plans for high-risk patients.
Researchers discovered a significant link between pregnancy and higher risk of melanoma, including increased death rates, metastasis, and recurrence.
Researchers have developed a class of compounds that inhibit acid ceramidase, an enzyme that accelerates tumor growth in melanoma. These compounds enhance the effect of anti-tumor drugs by making melanoma cells more prone to apoptosis.
Scientists at Sanford Burnham Prebys Medical Discovery Institute have identified a promising new melanoma drug, SBI-756. The compound targets the translation initiation complex and has been shown to inhibit melanoma cell growth. SBI-756 may offer a significant advantage in overcoming tumor resistance.